Reimagining Public Sector Analytics
Home News Governance Capgemini commits Rs 50 crore to boost Covid care in India

Capgemini commits Rs 50 crore to boost Covid care in India

Capgemini has committed Rs 50 crore to boost Covid care infrastructure including COVID care ICU facilities, oxygen generation plants, and relief operations in India

Aiman Ezzat, CEO of Capgemini (Photo: File)

IT consulting firm has committed Rs 50 crore to boost Covid care infrastructure including COVID care ICU facilities, oxygen generation plants, and relief operations in India.

The company said it is in discussions with various state government authorities to set up facilities across those cities where Capgemini has its presence. “This contribution will be in addition to the Capgemini CSR statutory fund in India,” said the company.

“At this critical time, we are committed to accelerate medical assistance in India through the Capgemini Social Response Unit. This fund will help to enhance the efforts of the Central and state authorities in building long-term medical infrastructure in India,” said , CEO of Capgemini.

The company said it is also contributing Rs 5 crores to UNICEF to provide immediate support across India for critical COVID response care, by setting up 3 oxygen generation plants and RT PCR testing machines to augment the government efforts to fight against .

“As we continue to support our colleagues, we are also striving to extend help to the communities we live in by providing access to critical care, which is required immediately for the fight against COVID-19 as well as medical needs in the coming years,” said , CEO of Capgemini in India.

The company said that during 2020, its social response unit provided 65 fully equipped ICU beds to three BMC hospitals in Mumbai, as well as 100 Oxygen Concentrators (OC) and 65 High Flow Nasal Cannulas (HFNC) to 15 government hospitals across Bengaluru. These ICU beds, which are fully equipped with ventilators, ECG monitors, and other critical ICU patient-monitoring devices, are currently being used to treat patients critically affected by COVID-19.

Exit mobile version